With a higher specificity of 92.0–99.4%, AFP-L3 is regarded as a more specific biomarker for HCC [72, 73]; however, it has a low sensitivity ranging from 18.8 to 37% for HCC, and may be not relevant to HCC with a total AFP level lower than 20 ng/mL [72–74]. This evidence concerns the gene AFP and hepatocellular carcinoma.